Adaptive Clinical Trial Designs: US FDA Provides Checklist To Begin Study
Executive Summary
Draft guidance specifies documentation that must be submitted to FDA prior to conducting an adaptive trial, and what to include in an application.
You may also be interested in...
US FDA’s COVID Master Protocol Guidance To Maintain Influence Post-Pandemic
Agency seeking comment on document intended to replace the just-issued guidance on COVID-19 treatment development as FDA stresses the value of master protocols for developing clinical knowledge.
Adaptive Clinical Trials: US FDA Offers More Advice On Bayesian Designs
Final guidance provides more details on clinical trial designs that use Bayesian adaptive features; says monitoring committee recommendations may deviate from the anticipated algorithm.
Latin America Notebook: Advancing Adaptive Trial Designs, Translating ICH Guidelines, Sharing Confidential Information
Brazil's drug regulator ANVISA will require more experience in dealing with adaptive trial designs before issuing guidance; translating older ICH guidelines remains a barrier to their implementation; and industry is asked to be more transparent in sharing their confidential information among drug regulators to facilitate convergence.